KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Long-Term Disease Control and Minimal Disease Activity of Head and Neck Atopic Dermatitis in Patients Treated with Tralokinumab up to 4 Years.

Raj Chovatiya, Simone Ribero, Andreas Wollenberg, Chang Ook Park, Juan Francisco Silvestre, H Chih-Ho Hong, Julien Seneschal, Hidehisa Saeki, Jacob P Thyssen, Christian Bjerregård Øland, Le Gjerum, Douglas Maslin, Andrew Blauvelt

Am J Clin Dermatol 26(4) 587-601

PMID40085349
PMCIDPMC12227490
DOI10.1007/s40257-025-00931-1
发表日期2025-03-14
入排依据:未发现恶性肿瘤人群证据。
已检查 6 张 PubMed Figure,均未识别为 KM 图:Fig. 1:AI 判定为 other;Fig. 2:AI 判定为 other;Fig. 3:AI 判定为 other;Fig. 4:AI 判定为 other;Fig. 5:AI 判定为 other;另有 1 张未列出。
摘要

摘要

BACKGROUND AND OBJECTIVE: There is a need for long-term atopic dermatitis (AD) treatments that can effectively improve AD involvement of the head and neck (H&N) region (referred to as H&N AD). Tralokinumab, a high-affinity monoclonal antibody that neutralizes interleukin-13, is approved for the treatment of moderate-to-severe AD. Recent real-world studies have observed the effectiveness of tralokinumab for H&N AD. Here, data from phase III parent trials, ECZTRA 1 and ECZTRA 2, and the long-term extension trial, ECZTEND, were used to assess impacts of long-term tralokinumab treatment on H&N AD and the association between improvements in H&N AD and patient quality of life, and to evaluate whether a proportion of patients developed paradoxical H&N erythema. METHODS: These post hoc analyses included data from all patients initiated on tralokinumab in ECZTRA 1 or ECZTRA 2. Patients were treated up to 4 years (i.e., up to 52 weeks in ECZTRA 1 or ECZTRA 2 plus up to 152 weeks in ECZTEND). Outcomes included body region subscores of the Eczema Area and Severity Index (EASI; H&N, upper limbs, trunk, lower limbs) and the Dermatology Life Quality Index (DLQI). Correlations between H&N EASI and DLQI were assessed with Spearman's correlation coefficient (ρ). The incidence of paradoxical H&N erythema (defined as H&N EASI erythema increasing from baseline to a score of 3, while all other regional EASI subscores are 0 or 1, during two or more consecutive visits) was also assessed. RESULTS: Overall, 1192 patients who were initiated on tralokinumab in ECZTRA 1 and ECZTRA 2, of whom 523 patients opted to continue in ECZTEND, were analyzed. Percentages of patients who had H&N EASI ≤ 1 increased from 12.2% at parent trial baseline to 87.2% by week 152 of ECZTEND. Improvements in EASI subscore outcomes from parent trial baseline were comparable across body regions throughout all timepoints of the study. At parent trial week 16, H&N EASI was moderately correlated with total DLQI (ρ = 0.47), with the strongest numerical correlations observed for DLQI questions regarding skin discomfort (ρ = 0.43) and embarrassment due to skin (ρ = 0.40). During up to 4 years of treatment, seven tralokinumab-treated patients exhibited paradoxical H&N erythema, five of whom improved to absent or mild H&N EASI erythema with continued tralokinumab treatment. CONCLUSIONS: Tralokinumab provided progressive and sustained improvements in H&N AD, with H&N EASI 0/1 observed in nearly 90% of patients treated up to 4 years. Improvements in H&N EASI were similar to improvements observed for other body regions and were associated with improvements in patient quality of life, particularly for skin discomfort and self-consciousness/embarrassment due to skin. CLINICAL TRIAL REGISTRATION: NCT03131648 (ECZTRA 1); study start date: 30 May, 2017; primary completion date: 7 August, 2018; study completion date: 10 October, 2019. NCT03160885 (ECZTRA 2); study start date: 12 June, 2017; primary completion date: 4 September, 2019; study completion date: 14 August, 2019. NCT03587805 (ECZTEND); study start date: 18 March, 2018; data cut-off date: 30 April, 2022; primary completion date: 3 July, 2024; study completion date: 3 July, 2024.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(6,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 1Fig. 1 Median head and neck Eczema Area and Severity Index (H&N EASI) in all patients initiated on tralokinumab in the parent trials up to 4 years of treatment. a Some patients did not opt to continue in ECZTEND following a protocol amendment in May 2021 prolonging the trial from 3 years to 5 years and decreasing visit frequency to every 16 weeks. Error bars illustrate the interquartile range (IQR) [third quartile to first quartile]. Clinical visits were conducted every 2 weeks up to week 16 in the parent trials. Patients responding at week 16 were followed every 2 weeks while patients moved to open-label were followed every 4 weeks up to week 52. There was variable time between last treatment in the parent trials and first treatment in ECZTEND (median [minimum, maximum] in days: 38 [0, 181]). Of the 671 patients who completed week 52 of the parent trials in countries with ECZTEND, 77.9% ( n = 523) of patients opted to continue in ECZTEND. n number of patients with observed data at the visit analyzed, Q2W , every 2 weeks, Q4W every 4 weeks, TCI topical calcineurin inhibitors, TCS topical corticosteroids
非 KM Figure
Fig. 2Fig. 2 Similar improvements observed across head and neck Eczema Area and Severity Index (H&N EASI) and other regional EASI subscores in all patients initiated on tralokinumab in the parent trials up to 4 years of treatment. a Standardized EASI or EASI subscore was calculated using median divided by respective maximum scale range (multiplied by 100). b Some patients did not opt to continue in ECZTEND following a protocol amendment in May 2021 prolonging the trial from 3 years to 5 years and decreasing visit frequency to every 16 weeks. Clinical visits were conducted every 2 weeks up to week 16 in the parent trials. Patients responding at week 16 were followed every 2 weeks while patients moved to open-label were followed every 4 weeks up to week 52. There was variable time between last treatment in the parent trials and first treatment in ECZTEND (median [minimum, maximum] in days: 38 [0, 181]). Of the 671 patients who completed week 52 of the parent trials in countries with ECZTEND, 77.9% ( n = 523) of patients opted to continue in ECZTEND. LL lower limbs, n number of patients with observed data at the visit analyzed, Q2W every 2 weeks, Q4W every 4 weeks, TCI topical calcineurin inhibitors, TCS topical corticosteroids, UL upper limbs
非 KM Figure
Fig. 3Fig. 3 Achievement of head and neck Eczema Area and Severity Index (H&N EASI) thresholds in patients with ( A ) H&N EASI ≥ 1 at baseline or ( B ) H&N EASI ≥ 4 at baseline who were initiated on tralokinumab in the parent trials up to 4 years of treatment. a Some patients did not opt to continue in ECZTEND following a protocol amendment in May 2021 prolonging the trial from 3 years to 5 years and decreasing visit frequency to every 16 weeks. Clinical visits were conducted every 2 weeks up to week 16 in the parent trials. Patients responding at week 16 were followed every 2 weeks while patients moved to open-label were followed every 4 weeks up to week 52. There was variable time between last treatment in the parent trials and first treatment in ECZTEND (median [minimum, maximum] in days: 38 [0, 181]). Of the 671 patients who completed week 52 of the parent trials in countries with ECZTEND, 77.9% ( n = 523) of patients opted to continue in ECZTEND. EASI-75 ≥ 75% improvement from baseline EASI, n number of patients with observed data at the visit analyzed, Q2W every 2 weeks, Q4W every 4 weeks, TCI topical calcineurin inhibitors, TCS topical corticosteroids
非 KM Figure
Fig. 4Fig. 4 Correlations between head and neck Eczema Area and Severity Index (H&N EASI) and total Dermatology Life Quality Index (DLQI) at parent trial baseline and week 16 in patients treated with tralokinumab. Each hexagon represents, by the intensity of its color, the count of patients defined in the area of the hexagon. Counts of patients <3 are defined with white hexagons . CI confidence interval, n number of patients with observed data at the visit analyzed, ρ Spearman’s correlation coefficient
非 KM Figure
Fig. 5Fig. 5 Achievement of head and neck Eczema Area and Severity Index (H&N EASI) erythema 0–1, 1.5–2.5, and 3 in ( A ) total population and ( B ) patients with H&N EASI erythema ≥ 2 at baseline who were initiated on tralokinumab in the parent trials up to 4 years of treatment. a Topical corticosteroid (TCS) use counted as rescue during initial 16 weeks (every 2 weeks [Q2W]) and 36-week maintenance treatment period (Q2W, every 4 weeks [Q4W]), whereas optional TCS use was permitted during open-label treatment (Q2W). There was variable time between last treatment in the parent trials and first treatment in ECZTEND (median [minimum, maximum] in days: 38 [0, 181]). Of the 671 patients who completed week 52 of the parent trials in countries with ECZTEND, 77.9% ( n = 523) of patients opted to continue in ECZTEND. Some patients did not opt to continue in ECZTEND following a protocol amendment in May 2021 prolonging the trial from 3 years to 5 years and decreasing visit frequency to every 16 weeks. n number of patients with observed data at the visit analyzed, TCI topical calcineurin inhibitors
非 KM Figure
Fig. 6Fig. 6 Median head and neck Eczema Area and Severity Index (H&N EASI) in all patients initiated on tralokinumab in the parent trials up to 4 years of treatment versus tralokinumab-treated patients who withdrew from the trials. a Some patients did not opt to continue in ECZTEND following a protocol amendment in May 2021 prolonging the trial from 3 years to 5 years and decreasing visit frequency to every 16 weeks. Error bars illustrate the interquartile range (IQR) [third quartile to first quartile]. Clinical visits were conducted every 2 weeks up to week 16 in the parent trials. Patients responding at week 16 were followed every 2 weeks while patients moved to open-label were followed every 4 weeks up to week 52. There was variable time between the last treatment in the parent trials and the first treatment in ECZTEND (median [minimum, maximum] in days: 38 [0, 181]). Of the 671 patients who completed week 52 of the parent trials in countries with ECZTEND, 77.9% ( n = 523) of patients opted to continue in ECZTEND. n number of patients with observed data at the visit analyzed, Q2W every 2 weeks, Q4W every 4 weeks, TCI topical calcineurin inhibitors, TCS topical corticosteroids, WD withdrawn
非 KM Figure